Αρχική World News The team tackling the serious side effects of cancer treatment in an...

The team tackling the serious side effects of cancer treatment in an ageing population

Anne Kiltie and her team.

By 2066, it’s predicted that around a quarter of the total UK population will be over 65 years old. A number approximately equivalent to the population of London.

This is in part due to increasing life expectancy, a result of progress made through medical research. But as life expectancy increases, an ageing population brings up a whole host of new challenges for healthcare, as we’ve blogged about before.

One of these problems is considering the side effects of cancer treatments, which can often be experienced more intensely by older patients.

We can see this with radiosensitisation, where additional treatment, such as small doses of chemotherapy, can be added to enhance the sensitivity of a tumour to radiotherapy.

But this comes at the cost of harmful side effects.

We caught up with Professor Anne Kiltie and PhD student, Chee Then, who are part of a team looking into the relationship between the gut microbiome and radiosensitisation in bladder cancer.

What is radiosensitisation?

A radiosensitiser can be thought of as an enhancer, an additional agent that increases the sensitivity of tumour cells to radiotherapy.

“So classically, radiotherapy was given on its own for any sort of tumour. And then people discovered that if you add a little bit of chemo at the same time as giving radiotherapyit acts locally to enhance the effects of the radiotherapy,” explains Kiltie.  

This is often the case for patients who are being treated for pelvic tumours including cervical, rectal and bladder cancers. The problem, Kiltie explains, is that the radiosensitising chemotherapy frequently results in increased toxicity in local organs and tissues, causing negative side effects.  

And these negative side effects may be too much for older people to cope with. Kiltie has witnessed this first-hand in her clinics. “The median age of my radiotherapy patients is about 81 to 82,” Kiltie explains, “and patients older than this end up having radiotherapy alone”.

So Kiltie and Then set out on the hunt for a radiosensitiser with reduced side effects, which led them to the gut.

Fibre consumption and the microbiome

The gut is one of the most widely researched parts of the body, but scientists are finding out eye-opening information about the gut and its unusual inhabitants every day.

More specifically, the trillions of bacteria, fungi and viruses that call the human body home, often called the microbiome.

The vibrant community of bugs can help protect us from harm, programming our immune system as well as providing nutrients for our cells. And it’s a real area of interest for cancer research.

Scientists, including our OPTIMISTICC Cancer Grand Challenges team, are interested in a whole host of possible links between the gut and cancer, from looking for cancer clues in poo, to discovering unique strains of bacteria that could act as a genetic marker for bowel cancer.

So far, changes to the gut microbiome enhancing anti-cancer treatment have only been explored in the context of chemotherapy and immunotherapy, “but there is not any study about radiotherapy and the gut microbiome,” says Then.

Because of its effect on the microbiome, scientists are also interested in the role that diet – particularly high fibre foods – can play in cancer. Previous studies have looked at how a high fibre diet has the capacity to reduce tumour growth, but haven’t looked explicitly at the mechanism behind how a high fibre diet could change the bacterial composition in the gut. 

Kiltie and her team wanted to explore this gap in the research by further examining the connection between the microbiome and radiotherapy.

Back to bacteria  

The lab focussed their work on mice with a compromised immune system and bladder cancer, who were fed a variety of fibre diets. “We treated the mice with either a low fibre diet, or a high soluble fibre or insoluble fibre diet or a mix of the two,” Then explains.

The team went on to analyse the composition of the gut microbiome of the different groups of mice, and how they responded to radiotherapy.

The team found that the mice fed with the high soluble fibre diet on average had the slowest tumour growth rate following small doses of radiotherapy.

Changes to fibre consumption can be seen almost immediately in the mice’s poo. With an indication of an increased amount of a short chain fatty acid known to confer anti-cancer effects, called butyrate.

Interestingly, and more unexpectedly, of the mice administered the high soluble fibre diet, those who responded to radiotherapy were enriched with a strain of bacterium known as Bacteroides acidifaciens. “A relatively newly-discovered bacterium, I suppose isolated in 2000,” Then comments.

The team believe the increase in the Bacteroides acidifaciens could be the missing link between the change in fibre consumption, short chain fatty acids and radiosensitisation. And that this bacterial strain plays a crucial role in the production of short chain fatty acids.

“So, the gut microbiota needs the fibre to produce short chain fatty acids and we think that this might be a potential radiosensitiser,” Then explains. 

Like Kiltie and Chee, Our Cancer Grand Challenges OPTIMISTICC team are also investigating correlations between the microbiome and treatment response. Some of their latest work has identified a bacterial strain which is associated with a higher chance of relapse of patients with rectal cancer who have been treated with chemotherapy.

From the lab to the clinic 

Kiltie and her team believe the proof is in the fibre. And it won’t take any expensive medicine to get this into practice, but repurposing of an existing treatment.

The team are looking into different types of fibre, including ispaghula husk. This is currently administered as a standard treatment for radiotherapy patients, but as a way to reduce diarrhoea.

Currently, patients “only start taking it halfway through their radiotherapy to help the side effects,” explains Kiltie. “But the argument is that the fibre can actually increase the short chain fatty acid production.”

The idea would be to get patients to take the fibre supplement before and during their radiotherapy to act as a radiosensitiser, whilst also reducing side effects. And most importantly, this would be something easily administered to older patients.

“The beauty of ispaghula husk, or whatever fibre supplement we end up giving, is it’s a medicine and old people take lots medicines and they’re generally pretty compliant,” says Kiltie. “To try and modify somebody’s diet is unlikely to work in a 78-year old, they’re probably going to say ‘no way’.” 

It’s early days, and the team have lots planned before they can trial it in humans, but the latest results are promising. “The idea has been kind of boiling, bubbling along for two or three years,” says Kiltie, “but to actually show something in the mice is really exciting.” 



Then, C.K., Paillas, S., Wang, X. et al. (2020). ‘Association of Bacteroides acidifaciens relative abundance with high-fibre diet-associated radiosensitisation’. BMC Biol 18, 102. DOI: https://doi.org/10.1186/s12915-020-00836-x 

More on this topic



Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...

Καρκίνος: Ευεργετική για τους καρκινοπαθείς η άσκηση

Σημαντικά ωφέλη προσφέρει η άσκηση, ακόμη και σε ασθενείς με καρκίνο. Οι περισσότεροι ασθενείς αγνοούν τα οφέλη που μπορεί να έχει γι’ αυτούς η συχνή...

Prostate Cancer

The article is provided by Scientific Communications Officer of NIPD Genetics, Ms Marina Charitou (MSc) Prostate Cancer Awareness Prostate cancer is the second most common cancer...
- Advertisment -

Ροή Ειδήσεων

Mother Spent 14 Weeks Battling Breast Cancer Alone During COVID-19 Lockdown

Battling cancer is difficult for anyone, but it’s even harder when you have to do it alone. That’s what happened to Samantha Currie. Samantha, 27,...

ESMO 2020: New Treatments for Advanced Kidney Cancer, Prostate Cancer, and Bladder Cancer

The 2020 European Society for Medical Oncology (ESMO) Virtual Congress was held online from September 19 to September 21. In this podcast, Neeraj Agarwal,...

The UK Government’s spending review: Time to invest in the future of cancer care

This autumn, the chancellor Rishi Sunak will go to Parliament and set out the UK Government’s spending priorities in the Comprehensive Spending Review...

Nivolumab Improves Survival for Some Patients with Advanced Stomach Cancer

October 20, 2020, by NCI Staff Some people with advanced stomach cancers may live longer if they are initially treated with nivolumab (Opdivo) and chemotherapy. Credit: National Cancer Institute Some...

Sugar and cancer – what you need to know

This post was first published in 2017 but has been reviewed and updated in October 2020. There’s a lot of confusing information and advice out...

FDA Extends Approval of Pembrolizumab for Classical Hodgkin Lymphoma

On 14 October 2020, the US Food and Drug Administration (FDA) extended the approval of pembrolizumab (KEYTRUDA®, Merck Sharp & Dohme Corp.) for the...